Preoperative HE4 expression in plasma predicts surgical outcome in primary ovarian cancer patients Results from the OVCAD study

E. I. Braicu*, C. Fotopoulou, T. Van Gorp, R. Richter, R. Chekerov, C. Hall, H. Butz, D. Cacsire Castillo-Tong, S. Mahner, R. Zeillinger, N. Concin, I. Vergote, J. Sehouli

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review


Objectives. Epithelial ovarian cancer (EOC) is the major cause of death due to gynecological malignancies. The most important prognostic factors are residual tumor mass after surgery and platinum-response. No predictive biomarkers are available to identify patients who will benefit from standard treatment. The aim of our study was to analyze the role of HE4 in predicting surgical and clinical outcome in primary EOC. Methods. In the European multicentric project "OVCAD", 275 consecutive patients with primary EOC were enrolled. Patients were eligible if radical cytoreductive surgery was performed and platinum-based chemotherapy was applied. Plasma and ascites samples were collected before or during surgery. The concentrations of HE4 and CA125 was determined using ELISA and Luminex technique, respectively. Results. Median age at first diagnosis was 58 years (range 18-85 years). Most patients presented with advanced stage disease, FIGO III or IV (94.6%), grades II-III (96%) and serous histology (86.2%). In most cases a complete cytoreduction to no residual tumor mass was achieved (68.4%). Higher plasma HE4 levels correlated with poor surgery outcome in terms of macroscopically residual tumor mass (p
Original languageEnglish
Pages (from-to)245-251
JournalGynecologic Oncology
Issue number2
Publication statusPublished - Feb 2013


  • Ovarian cancer
  • HE4
  • CA125
  • Surgical outcome

Cite this